<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1352">
  <stage>Registered</stage>
  <submitdate>27/10/2006</submitdate>
  <approvaldate>27/10/2006</approvaldate>
  <nctid>NCT00394186</nctid>
  <trial_identification>
    <studytitle>A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS)</studytitle>
    <scientifictitle>A Randomized, Double-Blind, Placebo-Controlled, Crossover, Phase IIa Study to Evaluate Efficacy and Safety of the Beta-3-Adrenergic Receptor Agonist Solabegron in Subjects With Irritable Bowel Syndrome</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>B3I105940</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Irritable Bowel Syndrome (IBS)</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - GW427353
Treatment: drugs - Placebo

Treatment: drugs: GW427353


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>completion of questionnaires by the subject, determining the average adequate relief rate</outcome>
      <timepoint>during the last 4 weeks of the treatment periods (weeks 3 to 6 in period 1 and weeks 15-18 in period 2)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood levels of GW427353</outcome>
      <timepoint>Week 1, 13</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Questionnaire</outcome>
      <timepoint>Weeks 1, 6, 12, 18, 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>ECG, vital signs, adverse events</outcome>
      <timepoint>each visit</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>clinical lab tests</outcome>
      <timepoint>Weeks 1, 6, 12, 18, 24</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>- Diagnosis of IBS which meets the Rome II criteria, screening pain score to be &gt; 1.5 (0=
        no pain, 4 = very severe pain)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects not meeting the Rome II criteria for the diagnosis of IBS

          -  Subjects with no stool for 7 days during the screen</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>100</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>GSK Investigational Site - Concord</hospital>
    <hospital>GSK Investigational Site - Caboolture</hospital>
    <hospital>GSK Investigational Site - Kippa Ring</hospital>
    <hospital>GSK Investigational Site - Spring Hill</hospital>
    <hospital>GSK Investigational Site - Adelaide</hospital>
    <hospital>GSK Investigational Site - Box Hill</hospital>
    <hospital>GSK Investigational Site - Malvern</hospital>
    <postcode>2139 - Concord</postcode>
    <postcode>4510 - Caboolture</postcode>
    <postcode>4021 - Kippa Ring</postcode>
    <postcode>4000 - Spring Hill</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3144 - Malvern</postcode>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Issoire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Les Sables d'Olonne</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Lille</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Saint Quentin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vitry sur Seine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Nordrhein-Westfalen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Sachsen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hamburg</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will test the hypothesis that GW427353, a beta-3 adrenergic agonist, will relieve
      IBS pain or discomfort and associated symptoms in IBS patients.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00394186</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials, MD</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>